داء كرون النشط من الدرجة المتوسطة إلى الشديدة عندما لا يحقق العلاج المضاد لـ TNF الهدأة

References

DOI: 10.14309/ajg.0000000000003465;

• Individuals are considered to have moderate–severe disease if they have not responded to treatment for mild–moderate disease or if they present with more prominent symptoms such as fever, significant weight loss, abdominal pain or tenderness, intermittent nausea or vomiting.
• We recommend upadacitinib use for induction and maintenance of remission for patients with moderate-to-severe CD who have previously been exposed to anti-TNF agents (strong recommendation, moderate level of evidence).
• We recommend the use of risankizumab as compared with ustekinumab in patients with moderate to severe CD and prior exposure to anti-TNF therapy (conditional recommendation, low level of evidence).
• The primary end points for induction (week 12) and maintenance (week 52) were clinical remission (defined as a CDAI score of <150) and endoscopic response.

View source ↗